First Proton Pump Inhibitor (PPI) With a Dual Delayed Release(TM) (DDR) Formulation DEERFIELD, IL and OSAKA, JAPAN–Jan 30, 2009 — Takeda Pathology Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today …
Biopharmaceuticals, Gastroenterology, FDA
Takeda Pharmaceutical, KAPIDEX, dexlansoprazole, Gastroesophageal Reflux Disease

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “FDA Approves KAPIDEX(TM) (Dexlansoprazole) Delayed Release Capsules for the Treatment of GERD”
Leave a Comment